{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T09:17:44Z","timestamp":1695633464251},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Classic Hodgkin lymphoma has a unique tumor composition in that there is a paucity of malignant cells present, and most of the tumor consists of normal immune and stromal cells. Despite the presence of an immune infiltrate within the tumor microenvironment, the malignant cells effectively evade the immune system and appear to utilize the presence of immune cells to promote the growth and survival of Hodgkin-Reed-Sternberg cells. Hodgkin-Reed-Sternberg cells evade immune detection because of overexpression of programmed death 1 ligands, PD-L1 and PD-L2, which suppress T-cell activation, and loss of expression of major histocompatibility complex molecules that prevent effective immune recognition. Recognition of these immune defects has led to clinical use of immune checkpoint blockade in classic Hodgkin lymphoma. Clinical trials using antibodies that block programmed death 1\/PD-L1 signaling have shown remarkable responses to therapy and have led to the approval of nivolumab and pembrolizumab for use in patients with relapsed and refractory disease. Trials are currently testing immune checkpoint blockade in earlier lines of therapy.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000331","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:55:42Z","timestamp":1538646942000},"page":"249-253","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response"],"prefix":"10.1097","volume":"24","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","year":"1987","journal-title":"J Clin Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOH.0000000000000158","article-title":"Targeting immune checkpoints in lymphoma","volume":"22","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","year":"1994","journal-title":"Immunity"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","year":"1997","journal-title":"Immunity"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","year":"2009","journal-title":"J Exp Med"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","year":"2008","journal-title":"Science"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2014preclinical background: CTLA-4 and PD-1 blockade","volume":"37","year":"2010","journal-title":"Semin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","year":"2011","journal-title":"Nature"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin's lymphoma: the pathologist's viewpoint","volume":"55","year":"2002","journal-title":"J Clin Pathol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1\u2013associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","year":"2009","journal-title":"Hum Pathol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.2437_54","article-title":"Blockade of the PD-1 checkpoint with anti\u2013PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL)","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood.V126.23.585.585","article-title":"Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","article-title":"A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 arms D and E)","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","article-title":"Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 CheckMate 205 study","volume":"130","year":"2017","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:11:40Z","timestamp":1695532300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000331","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}